Publications by authors named "G F Kieselbach"
Purpose: To analyze the cataract package variability in 1 country, Austria.
Setting: Austrian Departments of Ophthalmology.
Design: Cross-sectional study.
Purpose: To analyse the effect of intravitreal aflibercept injections on systemic angiopoietin-2 (Ang2) and vascular endothelial growth factor (VEGF)-A levels in patients with neovascular age-related macular degeneration (nAMD).
Methods: In a prospective, randomized study, aflibercept (2.0 mg/50 µl) or ranibizumab (0.
Objective: We compared visual and macular morphological outcomes after epiretinal membrane (ERM) peeling, with and without IVTA treatment.
Design: Interventional, retrospective, consecutive case-control study.
Participants: Forty-one eyes of 41 participants (17 men, 24 women) were included.
Purpose: To analyze the interaction between aflibercept and galectin-1 and evaluate the plasma levels of galectin-1 and vascular endothelial growth factor (VEGF)-A after intravitreal injection of aflibercept in patients with diabetic retinopathy (DR).
Methods: Interaction of galectin-1 with aflibercept was determined via immunoprecipitation. Seventeen patients with type 2 diabetes and diabetic macular edema (DME) were each treated with a single intravitreal injection of aflibercept (2.
Purpose: Placental growth factor (PlGF) has been implicated as a contributor to resistance against anti-VEGF therapy. The purpose of the present study was to analyze the systemic levels of PlGF, VEGF-A, and VEGF-B in patients with neovascular age-related macular degeneration (AMD) after treatment with aflibercept, ranibizumab, or bevacizumab.
Methods: Totals of 19 patients were treated with intravitreal aflibercept, 19 with ranibizumab, and 18 with bevacizumab.